Haloprogin is a topical antifungal agent. Its structure does not contain any of the functional groups typically exploited in hydrogen bond based co-crystal design. On the other hand, its 1-iodoalkyne moiety is nicely tailored to a crystal engineering strategy based on halogen bonding. Here we describe the formation of three polymorphs of haloprogin and of three co-crystals that this active pharmaceutical ingredient forms with both neutral and ionic co-crystal formers. The halogen bond plays a major role in all of the six structures and the interaction is thus confirmed to be a valuable tool which may complement the hydrogen bond when polymorphs and co-crystals of active pharmaceutical ingredients are pursued.
Graphical abstract: Polymorphs and co-crystals of haloprogin: an antifungal agent
Polymorphs and co-crystals of haloprogin: an antifungal agent
Michele Baldrighi,a Davide Bartesaghi,a Gabriella Cavallo,a Michele R. Chierotti,b Roberto Gobetto,b Pierangelo Metrangolo,*a Tullio Pilati,a Giuseppe Resnati*a and Giancarlo Terraneo*a
aNFMLab-Laboratory of Nanostructured Fluorinated Materials (NFMLab), Department of Chemistry, Materials, and Chemical Engineering “Giulio Natta”, Politecnico di Milano, Via L. Mancinelli 7, 20131 Milan, Italy
E-mail: email@example.com, firstname.lastname@example.org, email@example.com
bDepartment of Chemistry, Università di Torino, Via P. Giuria 7, 10125 Torino, Italy
CrystEngComm, 2014,16, 5897-5904
|Systematic (IUPAC) name|
|Legal status||Not available in U.S.|
|Mol. mass||361.39 g/mol|
|Melt. point||113.5 °C (236 °F)|
|Solubility in water||insoluble mg/mL (20 °C)|
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.
Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. Haloprogin is no longer available in the United States and has been discontinued.
U.S. Patent 3,322,813.
- “Haloprogin”. Drugs@FDA. Food and Drug Administration. Retrieved 2007-02-17.
- “Haloprogin”. DrugBank. University of Alberta. Nov 6, 2006. Retrieved 2007-02-17.